Cancer drug legacy Leverage GPC Biotech’s historical focus on anti-cancer drug development and their strategic merger with Agennix to explore partnerships or licensing deals around late-stage oncology candidates or platform technologies that can complement existing pipelines.

Clinical stage strength Target opportunities in clinical stage or near-market assets by highlighting capabilities in oncology R&D, regulatory strategy, and clinical data generation to potential buyers, partners, or co-development arrangements.

IPO and funding background Emphasize investor confidence and public-market experience to engage capital partners for financing clinical programs, especially for deals requiring multi-year funding or milestones aligned with trial progress.

Past merger synergies Position as a potential integrator or collaborator for larger biotech firms seeking niche oncology competencies or pipeline diversification that aligns with big players’ strategic priorities.

Technical readiness Offer technology-enabled services or partnerships around drug discovery support, data management, or computational biology to accelerate project milestones, leveraging the company’s historical tech stack capabilities.